Results 61 to 70 of about 69,242 (204)

Thrombotic thrombocytopenic purpura in pregnancy: Lessons from a case series of three patients

open access: yesJournal of International Medical Research
Thrombotic thrombocytopenic purpura is a rare but life-threatening complication during pregnancy. Historically, maternal mortality exceeded 90% before the introduction of therapeutic plasma exchange, which remains the cornerstone of treatment.
Sarah A Elkourashy   +4 more
doaj   +1 more source

Pediatric thrombotic thrombocytopenic purpura [PDF]

open access: yesEuropean Journal of Haematology, 2018
AbstractChild‐onset thrombotic thrombocytopenic purpura (TTP) is a rare entity of thrombotic microangiopathy (TMA). The pathophysiology of the disease is based on a severe functional deficiency of ADAMTS13 (activity <10%), the specific von Willebrand factor (VWF)‐cleavage protease.
Bérangère S. Joly   +2 more
openaire   +2 more sources

Caplacizumab in the Treatment of Patients with Recurrent Thrombotic Thrombocytopenic Purpura (TTP) [PDF]

open access: yesDocumenta Haematologica
We report two cases of recurrent thrombotic thrombocytopenic purpura, both patients without significant personal pathological antecedents, in which the evolution was favorable following the association of Caplacizumab with the classic treatment with ...
Mihaela-Sabrina HERDEA   +3 more
doaj   +1 more source

Potential Benefit of Ruxolitinib in Suspected Ocular and Neurological Transplant‐Associated Thrombotic Microangiopathy After Allogeneic Stem Cell Transplantation: A Case Report and Review

open access: yesClinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT We describe a rare case of suspected delayed‐onset TA‐TMA with ocular and neurological involvement following allo‐HSCT. The condition was refractory to standard therapies; neurological improvement was temporally associated with ruxolitinib initiation, suggesting a possible GVHD overlap.
Lise‐Marie Pillet   +13 more
wiley   +1 more source

Thrombotic thrombocytopenic purpura associated with Hodgkin lymphoma and non-Hodgkin lymphoma

open access: yes, 2018
Sir, Thrombotic thrombocytopenic purpura (TTP) is a rare haematological disease characterised by thrombotic microangiopathy in the setting of diminished ADAMTS13 enzyme activity.
Yaxley, Julian, Tomlinson, Ross
core   +1 more source

Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom [PDF]

open access: yes, 2010
Atypical haemolytic uraemic syndrome (aHUS) is associated with a poor prognosis with regard to survival at presentation, recovery of renal function and transplantation.
Sam Machin   +8 more
core   +1 more source

Is congenital thrombotic thrombocytopenic purpura a risk factor for ischemic osteonecrosis of the hip joint (Legg-Calvé-Perthes disease)?

open access: yesThrombosis Journal
Weise et al. reported on a 41-year-old patient previously diagnosed with congenital thrombotic thrombocytopenic purpura undergoing total hip replacement surgery for Perthes disease.
Alexander Laemmle, Bernhard Lämmle
doaj   +1 more source

Cancer‐Related Microangiopathic Haemolytic Anemia Revealing Occult Metastatic Gastrointestinal Signet‐Ring Cell Carcinoma: A Clinicopathological Case Report and Practical Differential Diagnostic Approach

open access: yesClinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT This case highlights key laboratory red flags and a failure to respond to standard treatment, both of which should prompt urgent investigation for occult malignancy in patients presenting with cancer‐related microangiopathic hemolytic anemia (CR‐MAHA).
Danijela Jovanovic   +4 more
wiley   +1 more source

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett   +15 more
wiley   +1 more source

Plasma Exchange for Hantavirus Pulmonary Syndrome: A Mechanistic Case for an Untested Intervention

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 5, October 2026.
ABSTRACT Hantavirus pulmonary syndrome (HPS) carries a case fatality rate of 35%–40% and has no approved pharmacologic treatment. Its pathophysiology is rooted in the plasma compartment: cytokines, viral antigens, immune complexes, and platelet‐binding glycoproteins circulate as drivers of immunopathologic endothelial injury, noncardiogenic pulmonary ...
Menatalla Nadim   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy